- Home
- GILD vs APP Comparison
GILD vs APP Comparison
Compare GILD & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- APP
- Stock Information
- Founded
- GILD 1987
- APP 2012
- Country
- GILD United States
- APP United States
- Employees
- GILD N/A
- APP N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- APP EDP Services
- Sector
- GILD Health Care
- APP Technology
- Exchange
- GILD Nasdaq
- APP Nasdaq
- Market Cap
- GILD 138.2B
- APP 115.5B
- IPO Year
- GILD 1992
- APP 2021
- Fundamental
- Price
- GILD $111.79
- APP $272.38
- Analyst Decision
- GILD Buy
- APP Buy
- Analyst Count
- GILD 27
- APP 20
- Target Price
- GILD $105.32
- APP $398.05
- AVG Volume (30 Days)
- GILD 10.7M
- APP 11.1M
- Earning Date
- GILD 04-24-2025
- APP 05-07-2025
- Dividend Yield
- GILD 2.83%
- APP N/A
- EPS Growth
- GILD N/A
- APP 363.16
- EPS
- GILD 0.38
- APP 4.53
- Revenue
- GILD $28,754,000,000.00
- APP $4,709,248,000.00
- Revenue This Year
- GILD $1.77
- APP $24.12
- Revenue Next Year
- GILD $3.52
- APP $23.17
- P/E Ratio
- GILD $294.18
- APP $60.07
- Revenue Growth
- GILD 6.04
- APP 43.44
- 52 Week Low
- GILD $62.07
- APP $60.67
- 52 Week High
- GILD $119.96
- APP $525.15
- Technical
- Relative Strength Index (RSI)
- GILD 57.43
- APP 41.58
- Support Level
- GILD $104.70
- APP $252.51
- Resistance Level
- GILD $107.42
- APP $352.00
- Average True Range (ATR)
- GILD 2.48
- APP 25.37
- MACD
- GILD -0.62
- APP 1.76
- Stochastic Oscillator
- GILD 57.74
- APP 31.36
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max, and gaming studios, which develop mobile games. AppLovin announced in February 2025 its plans to divest from the lower-margin gaming studios to focus exclusively on the ad tech platform. AppLovin's primary tool for future growth is Axon 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.